The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.
The Biomarker and Companion Diagnostics Virtual Conference scheduled to be held on 20-23 October 2020 would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers.
This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.
Vice President, Head, Translational Medicine, , Syncopation Lifesciences
Scientific Director, Translational Biomarker Research , Takeda
Senior Director, Clinical Pharmacology and Translational Medicine, Eisai
Clinical Professor , UCSF
Director, Program for Neuroproteomics and Biomarkers Research, University of Florida
Chief Scientific Officer, Proteome Sciences PLC
CEO and Founder, Thirty-Six
Chief Medical Officer , RareCyte, USA
Senior Research Scientist, Eli Lilly
Assistant Professor, Department of Genetics, Washington University School of Medicine
Assistant Professor, Pathology and Laboratory Medicine, University of Pennsylvania
Associate Professor, Radiology, Stanford University
Principal Scientist, Pathologist, Genentech
Professor, University of Arizona
Principal Scientist, Translational Medicine and Biomarkers, AbbVie
Head, Safety Biomarkers, Translational Sciences, Pfizer
Director, Product Development, Qiagen
Vice President, Alliances & CDx., Neogenomics
Ph.D. Technical Product Manager, Abcam
Scientist, DMPK, Takeda
Head of US Biopharma BD, Burning Rock Dx
Principal Scientist, Novartis
Head, Clinical and Translational Science, Owlstone Medical Ltd
Director, Oncology, Larvol
Director Oncology & Precision Diagnostics, QIAGEN, Germany
CEO , Eutropics Pharmaceuticals Inc.
Associate Vice President, Head, Global Marketing , Agilent, Denmark
CEO, Scientific Director, Cureline
Scientific Director of Companion Diagnostics, Exosome Diagnostics, A Bio-Techne Brand